ECM
MRNA icon

Everence Capital Management’s Moderna MRNA Stock Holding History

Everence Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527K Buy
10,380
+130
+1% +$6.07K 0.03% 362
2025
Q4 		$302K Hold
10,250
– – 0.02% 582
2025
Q3 		$265K Hold
10,250
– – 0.02% 657
2025
Q2 		$283K Sell
10,250
-6,460
-39% -$170K 0.02% 605
2025
Q1 		$474K Buy
16,710
+8,770
+110% +$311K 0.03% 384
2024
Q4 		$330K Sell
7,940
-1,390
-15% -$66.4K 0.02% 533
2024
Q3 		$624K Hold
9,330
– – 0.04% 354
2024
Q2 		$1.03K Hold
9,330
– – 0.07% 221
2024
Q1 		$994 Hold
9,330
– – 0.07% 242
2023
Q4 		$928K Buy
9,330
+1,170
+14% +$98.4K 0.07% 248
2023
Q3 		$843 Hold
8,160
– – 0.07% 247
2023
Q2 		$1.04M Hold
8,160
– – 0.08% 201
2023
Q1 		$1.25K Hold
8,160
– – 0.1% 171
2022
Q4 		$1.47K Sell
8,160
-2,420
-23% -$396K 0.13% 157
2022
Q3 		$1.25M Hold
10,580
– – 0.12% 156
2022
Q2 		$1.51M Buy
10,580
+2,480
+31% +$354K 0.13% 137
2022
Q1 		$1.4M Hold
8,100
– – 0.11% 158
2021
Q4 		$2.06M Buy
8,100
+3,730
+85% +$1.09M 0.15% 119
2021
Q3 		$1.68M Buy
+4,370
New +$1.61M 0.14% 130

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Everence Capital Management's MRNA Position: Q1 2026 in Review

Everence Capital Management increased its Moderna (MRNA) stake by 1.3% in Q1 2026, buying an estimated $6.07K and bringing the position to 10,380 shares worth $527K. The position accounts for 0.03% of the portfolio, ranked #362.

Everence Capital Management first reported a position in MRNA in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.06M in Q4 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Everence Capital Management held 10,380 shares of Moderna worth $527K as of Q1 2026.
  • Everence Capital Management bought 130 Moderna shares in Q1 2026, an estimated $6.07K.
  • Moderna made up 0.03% of Everence Capital Management's portfolio in Q1 2026, its #362 holding.
  • Everence Capital Management first reported a position in Moderna in Q3 2021 and has held it in 19 quarters since.
  • Everence Capital Management's Moderna position peaked at $2.06M in Q4 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.